Drug Trial Radar · NCT05468489
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 18, 2022
Primary completion
Feb 28, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC. Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows: * Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide) * Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Conditions
- Extensive Stage Small Cell Lung Cancer
Interventions
Serplulimab + chemotherapy (carboplatin-etoposide)Drug
Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics
Atezolizumab + chemotherapy (carboplatin-etoposide)Drug
Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: A period from randomization through death regardless of causality (approximately up to 24 months).
Locations
65 sites in 1 country. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
City of Hope - Phoenix
Goodyear, Arizona
Arizona Clinical Research Center (ACRC)
Tucson, Arizona
Highlands Oncology Group
Springdale, Arkansas
Compassionate Care Research Group
Fountain Valley, California
Providence Medical Foundation
Fullerton, California
Los Angeles Cancer Network
Glendale, California
OPN - Oncology Physician Network
Los Alamitos, California
Kaiser Permanente Research (Southern California)
Los Angeles, California
UC Davis
Sacramento, California
UCHealth Memorial Hospital North
Colorado Springs, Colorado
MD Anderson- North Colorado Medical Center
Greeley, Colorado
Advanced Cancer Treatment Centers
Brooksville, Florida
Cancer Specialists North Florida
Jacksonville, Florida
Mount Sinai Comprehensive Cancer Center
Miami, Florida
Florida Cancer Affiliates- (Ocala Oncology - Main)
Ocala, Florida
Mid Florida Hematology and Oncology Center
Orange City, Florida
BRCR Global
Plantation, Florida
Napa Research
Pompano Beach, Florida
Advanced Research
Tamarac, Florida
Straub Benioff Medical Center
Honolulu, Hawaii
City of Hope- Chicago
Chicago, Illinois
Cancer Center of Decatur
Decatur, Illinois
Accellacare of Duly
Tinley Park, Illinois
Northwest Cancer Centers
Dyer, Indiana
Cancer Center of Kansas
Wichita, Kansas
Baptist Health Lexington
Lexington, Kentucky
Pikeville Hospital
Pikeville, Kentucky
CHRISTUS St. Frances Cabrini Cancer Center
Alexandria, Louisiana
Pontchartrain Cancer Center
Hammond, Louisiana
Henry Ford Health Providence Southfield Hospital
Southfield, Michigan
Health Partners Cancer Center at Regions Hospital
Saint Paul, Minnesota
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi
MidAmerica Division Inc., c/o Research Medical Center
Kansas City, Missouri
Lake Regional
Osage Beach, Missouri
St. Vincent Frontier Cancer Center
Billings, Montana
University of Nebraska Medical Center
Omaha, Nebraska
Renown Health
Reno, Nevada
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Regional Cancer Care Associates LLC RCCA
Freehold, New Jersey
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.